SIGA is a monkeypox play. Creator of TPoxx, a popular FDA approved treatment for the disease. Surge in demand incoming as this virus gains traction with outbreaks in numerous countries that have never dealt with the virus before. Post COVID I'd expect an uptick in orders for TPoxx treatment as countries will likely react and or over react to the risk of broader outbreaks.
Company is trading a high PE at the moment but with bolstered sales I'd expect the upcoming quarters to demonstrate increased sales and increased demand for the treatment. If the cases continue to grow the mainstream media will pick this up and run with the fear to drive ratings.
Tracking the cdc site for active cases and as long as the numbers are rising SIGA seems like a viable play short term.
https://www.cdc.gov/poxvirus/monkeypox/response/2022/world-map.html
Thought not airborne like COVID the virus is nasty and will gain attention as the symptoms and outbreaks continue.
There are other plays in this space, but SIGA looks strong and I can easily see a $30 price target. Good luck and I would love to hear some thoughts on this play. I got in at 16.71 and am building a position as long as case count keeps rising.
Additionally the virus has no rapid test. Long incubation period up to 21 days and the virus can live on surfaces long enough to transmit from those with the monkey pox skin sores. There are likely many more cases out there than reported, and many countries let this get out of hand before containing the outbreaks.
Leave a Reply